Navigation Links
Oncobiologics Fills Key Leadership Positions and Names Scientific Advisory Board
Date:5/25/2012

CRANBURY, N.J., May 25, 2012 /PRNewswire/ -- Oncobiologics, Inc. announced today that it has filled two important leadership positions with established biopharmaceutical industry experts. Stephen J. McAndrew, Ph.D. is now Vice President, Business Development and Vincent J. Benn, Ph.D. has joined the company as Vice President, Clinical & Regulatory Affairs. The company also announced its new Scientific Advisory Board, which will be headed by Joseph Bertino, M.D., currently Chief Scientific Officer and Associate Director of the Cancer Institute of New Jersey at UMDNJ-Robert Wood Johnson Medical School.

"Oncobiologics is fortunate to add pros like Steve and Vince to our management team. Their interest in Oncobiologics is an indication that our existing team and recent technical progress continue to attract the best and the brightest from the industry," said Oncobiologics Founder & CEO Pankaj Mohan, Ph.D. 

Mohan continued, "In addition, the establishment of our Scientific Advisory Board with Dr. Bertino at the helm is a watershed moment for Oncobiologics. This external group of experts will provide critical clinical and strategic direction to guide the progress of our novel biotherapeutics." 

Dr. McAndrew is responsible for the company's revenue growth strategy and initiatives, establishing and managing all collaborative research and commercial product partnerships, and sourcing selected investment opportunities. Prior to joining Oncobiologics, Dr. McAndrew served as Vice President, Business Development for Xenogen Biosciences, Caliper Life Sciences and Taconic Biosciences. Previously, he served as Vice President, Pharmaceutical Business Development for Lexicon Pharmaceuticals and Director, Biotechnology Licensing for Bristol-Myers Squibb Company. Earlier, Dr. McAndrew led applied research programs within Discovery-Oncology at Bristol-Myers Squibb, and exploratory research in the Roche Institute of Molecular Biology at Hoffmann La-Roche.

Dr. Benn is responsible for Oncobiologics' clinical programs, regulatory strategies and regulatory affairs. He brings more than 30 years of clinical and regulatory drug and biologics development experience to Oncobiologics. Previously, he was Vice President Clinical & Regulatory Affairs at Essential Pharmaceuticals, Vice President Worldwide Clinical Operations at Discovery Labs, and Global Clinical Program Director at Aventis Behring LLC. He brings extensive experience in the development and defense of clinical development plans before FDA, EMEA, MCA, MPA, and the Paul Erlich Institute (PEI).

In addition to Dr. Bertino, Scientific Advisory Board members include Debabrata Banerjee, Ph.D., Associate Professor of Medicine & Pharmacology at Robert Wood Johnson Medical School & Adjunct Associate Prof at New York Medical College; Igor A. Astsaturov, M.D., Ph.D., Assistant Professor and Attending Oncologist at Fox Chase Cancer Center in Philadelphia; Hossein Borghaei, D.O., M.S., Director of Thoracic Medical Oncology and Co-Leader, Thoracic Cancer Service at Fox Chase Cancer Center; Matt Robinson, Ph.D., Assistant Professor in the Developmental Therapeutics Program at Fox Chase Cancer Center; Mak Jawadekar, Ph.D., formerly Director, Portfolio Management & Analytics, Pfizer, Inc. and Vice President of Asia CRG at Pfizer Inc.; and Mauricio Futran, Ph.D., Professor and Chair of Chemical and Biochemical Engineering at Rutgers University, with nearly 30 years of experience at Merck & Co. and Bristol-Myers Squibb.

About Oncobiologics, Inc.

Headquartered in Cranbury, N.J., Oncobiologics is a biopharmaceutical company developing a pipeline of next-generation biotherapeutics focused on clinically validated targets in the therapeutic areas of oncology, immuno-oncology, and immunology. The company's proprietary TRIDENT™ platform leverages fully human single-chain, bi-specific antibodies with HSA binding designed for overall significantly enhanced efficacy, safety, and pharmacokinetics with targeted delivery. For more information, please visit www.oncobiologics.com or call 609-619-3990.

Contact:

Rick Gregory
R.C. Gregory & Co.
860-677-2377
rick@rcgregory.com

This press release was issued through eReleases® Press Release Distribution. For more information, visit http://www.ereleases.com.


'/>"/>
SOURCE Oncobiologics, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. Oncobiologics Appoints Scott Canute, Former President of Eli Lilly and Genzyme, to its Board of Directors
2. Oncobiologics, Inc. to Unveil New Biologics Proof-of-Concept Engine at BIO International Convention
3. FirstMarks Landmark Clinical Study Successfully Completed that Fulfills the Unmet Need to Access the Risk of Near Term MI
4. Sanford Rose Associates® - Minneapolis Fills Key Management Position for the Micromedics Operation of Nordson Corporation
5. RBC Life Sciences Fills Newly Created Vice President of Sales and Marketing Position With Industry Veteran
6. New Pleio Medication Adherence Service Increases Prescription Refills Up To 53%
7. Micromet, Inc. Fills Audit Committee Vacancy and Regains Compliance With NASDAQ Marketplace Rule
8. USC Marshall School of Business 6th Annual Leadership Summit
9. More than half of Americans doubt US global leadership in 2020
10. Auxilium Announces Appointments to Enhance Leadership Team
11. Berkeley Lab seeks to help US assert scientific leadership in critical materials
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/27/2016)... 2016 NanoStruck Technologies Inc. ... ( Frankfurt : 8NSK) gibt bekannt, ... 13. August 2015 die Genehmigung von der CNSX ... 200.000.000 Einheiten auf 400.000.000 Einheiten zu erhöhen, um ... wurden 157.900.000 Einheiten mit dem ersten Teil der ...
(Date:4/27/2016)... , ... April 27, 2016 , ... ... is pleased to announce the appointment of John Tilton as Chief Commercial Officer.  ... Director and one of the founding commercial leaders responsible for the commercialization of ...
(Date:4/27/2016)... ... 27, 2016 , ... PathSensors, Inc., a leading environmental testing ... will assist PathSensors in expanding the use of the company’s CANARY® technology in ... platform for the detection of harmful pathogens, including a number of bacteria, viruses, ...
(Date:4/27/2016)... ... 2016 , ... Global Stem Cells Group CEO Benito Novas announced ... of GSCG affiliate Kimera Labs in Miami. , In 2004, Ross received his Ph.D. ... for hematologic disorders and the suppression of graft vs. host disease (GVHD) under UM ...
Breaking Biology Technology:
(Date:3/10/2016)... BLUE BELL, Pa. , March 10, 2016   ... U.S. Customs and Border Protection (CBP) is testing ... in San Diego to help identify ... United States . The test, designed to help determine ... outdoor, pedestrian environment, began in February and will run until ...
(Date:3/8/2016)... March 8, 2016   Valencell , the ... announced it has secured $11M in Series D ... a new venture fund being launched by UAE-based ... from existing investors TDF Ventures and WSJ Joshua ... continue its triple-digit growth and accelerate its pioneering ...
(Date:3/2/2016)... 2016 http://www.researchandmarkets.com/research/wzwqtz/global_biometrics ... the  "Global Biometrics Market in Hospitality Sector ... http://photos.prnewswire.com/prnh/20130307/600769) , , Global biometrics market in ... CAGR of around 27%   --> ... the addition of the  "Global Biometrics Market ...
Breaking Biology News(10 mins):